ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VOR / insiders
IMTX (44) INBX (18) TSHA (31) LYCA (54) ⌘ Pro Terminal →

Vor Biopharma Inc. (VOR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$19.25 -2.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.14

Vor Biopharma Inc. (VOR) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $1.16B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Vor Biopharma Inc. (NASDAQ: VOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $19.25 (-2.18% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VOR ranks #420 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VOR compare to IMTX and INBX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VOR carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and INBX (Inhibrx Biosciences Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.06B). Among the 5-stock peer group, VOR leads on earnings multiple (N/A) while VOR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VOR?
▼

Per VOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817229), Vor Biopharma Inc. generated $1.04B in revenue (+206.7% YoY), -$696.0M in net income, and -$143.7M in free cash flow against $464.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.14 (-0.58%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (8)Whales (10)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
$27 Bull$18 Base$14 Bear
📬 FREE VOR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY VOR SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 65% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$19.06-0.2% Next Q
Q2 (-2Q)
37
Grade E$19.03+2.7% Next Q
Q3 (-1Q)
39
Grade E$19.54-1.5% Next Q
Current
42
Grade D-$19.25-7% Hist 90D α
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VOR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VOR currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.64) and Max Pain ($20.21) forces dealer call-delta covering toward $27.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

VOR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VOR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VOR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VOR)

  • ✓Walkthrough of VOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.86%▲ ASCENDING CHANNEL
2026-11-03O $20.91H $20.91L $19.25C $19.25VOL 759.6K
RES: $29.29SUP: $17.79SMA50: $20.64SMA200: $17.39
$26.94$23.05$19.16$15.26$11.37RES $29.29SUP $17.79$19.252026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VOR Butterfly Map → + Track VOR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +206.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VOR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VOR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VOR)

Health Care Rank #420 of 1015 ⚔️ IMTX vs VOR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VOR vs. IMTX, INBX, TSHA, LYCA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vor Biopharma Inc. (VOR) ranks #420 by composite RQD confidence (42/100, grade D-) and #336 by equity capitalization ($1.16B). Within this direct 5-issuer industry benchmark cohort, VOR leads on earnings valuation at N/A trailing P/E, while VOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with VOR at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VOR ACTIVE
Vor Biopharma Inc.
D- 42/100 — — -35.0% -2.18% $1.16B Benchmark Subject
IMTX
Immatics N.V.
D 44/100 — — — -1.94% $1.08B /imtx-vs-vor →
INBX
Inhibrx Biosciences Inc.
E 18/100 — — -35.0% +0.53% $1.06B /inbx-vs-vor →
TSHA
Taysha Gene Therapies Inc.
E 31/100 — — -35.0% -3.15% $1.35B /tsha-vs-vor →
LYCA
Lycia Therapeutics Inc.
D+ 54/100 — — — +2.96% $1.38B /lyca-vs-vor →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817229 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vor Biopharma Inc. (VOR) reported GAAP revenue of $1.04B (+206.7% vs. FY2024 revenue of $339.3M , and +194.9% cumulative change since FY2023) , GAAP net income of -$696.0M, operating cash flow of -$142.7M, and free cash flow of -$143.7M (-43.8% YoY). On the balance sheet, VOR closed FY2025 with $464.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.04B -$696.0M -$142.7M -$143.7M $464.1M —
FY2024 (FY) 2024-12-31 $339.3M -$116.9M -$99.7M -$99.9M $142.9M —
FY2023 (FY) 2023-12-31 $352.9M -$117.9M -$100.3M -$100.3M — —

3. VOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vor Biopharma Inc. (NASDAQ: VOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $19.25 (-2.18% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VOR ranks #420 in composite RQD confidence.

How does VOR compare to IMTX and INBX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VOR carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and INBX (Inhibrx Biosciences Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.06B). Among the 5-stock peer group, VOR leads on earnings multiple (N/A) while VOR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VOR?

Per VOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817229), Vor Biopharma Inc. generated $1.04B in revenue (+206.7% YoY), -$696.0M in net income, and -$143.7M in free cash flow against $464.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VOR trading relative to its 50-day, 200-day, and 52-week technical levels?

VOR last traded at $19.25 (-2.18% on volume of 624,100 shares), positioning the stock -6.73% below its 50-day simple moving average ($20.64) and +10.70% above its 200-day simple moving average ($17.39). Across its 52-week range of $6.50 to $26.00, VOR sits at the 65.4% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.84 to $21.66).

Direct Sub-Reports: VOR RQD Cockpit VOR 12M Forecast VOR Earnings & Move VOR Dividends & DRIP VOR Insiders & 13F VOR Whale Options VOR Profit Sankey VOR News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

VOR — Vor Biopharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vor Biopharma Inc. (VOR) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $19.25 (-2.18% 1D, market capitalization $1.16B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -11.61%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vor Biopharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vor Biopharma Inc. (VOR) reported $1.04B in annual revenue (up from $339.3M in FY2024, +206.7% YoY) and -$696.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($352.9M revenue, -$117.9M net income) through FY2025, VOR scaled operating cash flow to -$142.7M and free cash flow to -$143.7M, backed by $464.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.61% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $6.50 – $26.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), VOR carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can VOR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.04B and free cash flow of -$143.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VOR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VOR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vor Biopharma Inc. (VOR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VOR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VOR Bull vs. Bear Conversation Board — What's Your Call at $19.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VOR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VOR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $23.03 (+17.0%)
📌 Pinned Debate

Cash rose to $396.5M in FY 2025 from $81.9M in FY 2024, and the stock is up 1.26% on the session.

The street is overcomplicating Vor Biopharma Inc. (VOR). Cash rose to $396.5M in FY 2025 from $81.9M in FY 2024, and the stock is up 1.26% on the session.. With an RQD score of 42/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $21.25.

EarningsSniper 🐂 BULL

Both sides have a point here — VOR's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $15.35 (-22.0%)
Spot @ $19.68

ROIC is -35%, FCF yield is -11.61%, and the RQD rating scores insider conviction at only 3 of 20.

I respect the product at Vor Biopharma Inc., but the stock at $19.68 is a different story. ROIC is -35%, FCF yield is -11.61%, and the RQD rating scores insider conviction at only 3 of 20.. FCF yield is -11.61% and RQD sits at 42/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE